ReviewBiomarker research2026
The JAK-STAT pathway in allergic diseases: from pathogenesis to targeted therapy.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The JAK-STAT signaling pathway serves as a central hub in the pathogenesis of various allergic diseases, including atopic dermatitis, allergic rhinitis, and asthma. It mediates signal transduction of key inflammatory cytokines, such as IL-4, IL-5, and IL-13, and directly regulate regulating Th2 cell differentiation, IgE production, and eosinophil function. Moreover, the dysregulation of its intrinsic negative feedback mechanisms also serves as a significant driver of disease progression. Targeting this pathway has yielded significant progress in drug development, including JAK/STAT inhibitors and immunomodulatory natural products. However, challenges persist in regarding long-term safety, efficacy differences across disease subtypes, and combination therapy approaches. This review systematically outlines the central role of the JAK-STAT pathway in allergic diseases and comprehensively evaluates recent advances and clinical prospects of related targeted therapies, aims to provide a comprehensive reference for future basic research and precise clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.